Sodium Oxybate

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Narcolepsy

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (2)
EU
  • Treatment of narcolepsy with cataplexy in adult patients (Xyrem)
Product first approved 2005EMA
CA
  • Cataplexy in patients with narcolepsy (Xyrem)
Product first approved 2005cdn.clinicaltrials.gov

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (10)
Narcolepsy
NCT02720744 · Avadel
2016-11-17 – 2020-03-25 · Excessive Daytime Sleepiness, Cataplexy, Narcolepsy
What this study did
NCT00132873 · Jazz Pharmaceuticals
2004-10 – 2007-12 · Narcolepsy
What this study did
NCT00066170 · Jazz Pharmaceuticals
2003-04 – 2004-11 · Narcolepsy
What this study did
NCT00049803 · Orphan Medical
2000-12 – 2004-04 · Narcolepsy
What this study did
Other / comorbidity
NCT02637648 · Ramin Khatami
2015-12 – 2017-06 · Cluster Headache
What this study did
NCT00423605 · Jazz Pharmaceuticals
2006-12 – 2010-01 · Fibromyalgia
What this study did
Phase 2/3 (3)
Other / comorbidity
NCT03292458 · Kristina Simonyan
2018-01-22 – 2024-10-11 · Spasmodic Dysphonia, Voice Tremor
What this study did
NCT03597555 · University Hospital, Montpellier
2018-10-18 – 2023-04-12 · Idiopathic Hypersomnia
What this study did
NCT00514995 · Lindner Center of HOPE
2007-08 – 2011-04 · Binge Eating Disorder
What this study did
Phase 2 (12)
Narcolepsy
NCT06809803 · Stanford University
2025-10-27 – 2027-07 · Narcolepsy Type 1 (NT 1)
What this study did
Other / comorbidity
NCT07596342 · Assistance Publique - Hôpitaux de Paris
2026-06 – 2027-10 · Sleep Disorder (Disorder), Critical Care
What this study did
NCT04082806 · Erich Seifritz
2020-08-06 – 2022-04-06 · Major Depressive Disorder
What this study did
NCT01961297 · Kristina Simonyan
2012-07 – 2017-06-30 · Spasmodic Dysphonia, Voice Tremor
What this study did
NCT02111122 · Christian Baumann
2014-04 – 2016-08 · Sleep-wake Disturbances in Motor-phase Parkinson's Disease
What this study did
NCT00744393 · Tufts Medical Center
2008-10 – 2009-12 · Mechanically Ventilated ICU Patients
What this study did
NCT00383643 · Stanford University
2006-05 – 2009-12 · Sleep Initiation and Maintenance Disorders
What this study did
NCT00594256 · Nathan Kline Institute for Psychiatric Research
2008-05 – 2009-04 · Schizophrenia, Insomnia Related to Schizophrenia (307.42)
What this study did
NCT00598078 · Jazz Pharmaceuticals
2007-12 – 2008-12 · Essential Tremor
What this study did
NCT00641186 · Baylor College of Medicine
2004-09 – 2008-11 · Parkinson Disease
What this study did
NCT00330291 · State University of New York - Upstate Medical University
2005-08 – 2006-08 · PTSD, Anxiety, Post Traumatic
What this study did
NCT00087555 · Jazz Pharmaceuticals
2004-07 – 2006-01 · Fibromyalgia
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT00931164 · University of Utah
2009-08 – 2011-09 · Alternating Hemiplegia of Childhood
What this study did
Phase 1 (4)
Narcolepsy
NCT03626727 · Brigham and Women's Hospital
2020-09 – 2020-09-01 · Hypersomnia, Narcolepsy, Traumatic Brain Injury
What this study did
NCT00345800 · UCB Pharma SA
2006-04-10 – 2008-01-22 · Narcolepsy With Cataplexy
What this study did
Other / comorbidity
NCT07041203 · Kristina Simonyan
2026-10-01 – 2027-09-30 · Spasmodic Dysphonia, Laryngeal Dystonia, Voice Tremor
What this study did
NCT00058955 · Orphan Medical
2003-08 – 2005-03 · Sedative Abuse
What this study did
Phase 4 (11)
Narcolepsy
NCT02637076 · Centre for Addiction and Mental Health
2016-01 – 2020-01-23 · Narcolepsy With Cataplexy, Healthy Controls
What this study did
Other / comorbidity
NCT05085873 · Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
2021-10-14 – 2023-10-10 · Palliative Care
What this study did
NCT04006925 · Stanford University
2019-09-10 – 2022-02-01 · REM Sleep Behavior Disorder, Parkinson Disease
What this study did
NCT01584934 · University Hospital, Ghent
2013-06 – 2015-12 · Chronic Fatigue Syndrome
What this study did
NCT02055898 · Imperial College London
2014-04 – 2015-08 · Chronic Fatigue Syndrome
What this study did
NCT04648423 · Laboratorio Farmaceutico Ct S.r.l.
2001-07-23 – 2012-01 · Alcohol Use Disorder (AUD), Alcohol Dependence
What this study did
NCT00706186 · Clayton Sleep Insititute
— · Mild Alzheimer's Disease
What this study did
NCT02090504 · Catholic University of the Sacred Heart
2002-02 – 2009-05 · Alcohol Withdrawal Syndrome, Alcohol Dependence
What this study did
NCT00498485 · University of Medicine and Dentistry of New Jersey
2007-05 – 2008-12 · Chronic Fatigue Syndrome
What this study did
NCT00506974 · St. Luke's Hospital, Chesterfield, Missouri
2007-05 – 2008-06 · Sleep
What this study did
NCT00086281 · Jazz Pharmaceuticals
2003-11 – 2005-11 · Obstructive Sleep Apnea Syndrome
What this study did
Early phase / not applicable (2)
Other / comorbidity
NCT07794982 · Jingsheng Lou
2026-09-01 – 2027-12 · Thoracic Surgical Procedures
What this study did
NCT02063217 · Washington University School of Medicine
2013-12 – 2016-07 · Amyloid-beta
What this study did
Used as active comparator (2)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 1 (1)
Narcolepsy
NCT02215499 · Concert Pharmaceuticals
2014-07 – 2014-11 · Narcolepsy, Excessive Daytime Sleepiness
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT04508166 · Psychiatric University Hospital, Zurich
2021-10-01 – 2022-01-29 · Intrusive Thought, Psychological Trauma, Inflammatory Response, Physiological Stress
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Narcolepsy: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Sodium Oxybate: this drugApprovedSmall moleculeGABA-B receptorPartial signalFeatured results are non-efficacy only in this race
Calcium, Magnesium, Potassium And Sodium Oxybates (Xywav)ApprovedSmall moleculeGABA-B receptornot yet gradedNo reviewed efficacy summary in this indication
Modafinil (Provigil)ApprovedSmall moleculeSympathomimetic-like Agentnot yet gradedNo reviewed efficacy summary in this indication
Oveporexton (Orzeyful)ApprovedSmall moleculeOrexin-2 receptor (agonist)not yet gradedNo reviewed efficacy summary in this indication
Pitolisant (Wakix)ApprovedSmall moleculeHistamine H3 receptor (antagonist / inverse agonist)Reliable signal
NCT02611687: To Evaluate the Efficacy of Pitolisant in Reducing Residual Excessive Daytime Sleepiness (EDS), Ullanlinna Narcolepsy Scale Score. (8 weeks): Pitolisant -6.29 score on a scale (Standard Error 1.14) | Placebo -2.6 score on a scale (Standard Error 1.35)
Solriamfetol (Sunosi)ApprovedSmall moleculeDopamine/norepinephrine transporterPartial signal
NCT02348632: Change in Epworth Sleepiness Scale score from the start to the end of the 2-week randomized-withdrawal period (positive = worse): +1.6 with continued solriamfetol (n=139) vs +5.3 after switch to placebo (n=141); difference -3.7 points (95% CI -4.8 to -2.7), significant after multiplicity adjustment (SUNOSI label Table 8; CT.gov posted results).
NCT02348593: Change from baseline to week 12 vs placebo: MWT +12.3 (300 mg) and +9.8 (150 mg) vs +2.1 minutes; ESS -6.4 and -5.4 vs -1.6 points (all p<0.0001). The 75 mg dose (MWT +4.74, ESS -3.8) was not statistically significant on either coprimary (Thorpy et al., Ann Neurol 2019; SUNOSI label).
AlixorextonPhase 3Small moleculeOrexin-2 receptor (agonist)not yet gradedNo reviewed efficacy summary in this indication
ReboxetinePhase 3Small moleculenorepinephrine transporterPartial signal
NCT05113745: Primary endpoint, change in frequency of cataplexy attacks in the randomized withdrawal phase: statistically significant improvement vs placebo (Axsome, 2024-11-26).
CleminorextonPhase 2/3Small molecule—not yet gradedNo reviewed efficacy summary in this indication
TAK-360Phase 2/3Small moleculeOrexin-2 receptor (agonist)not yet gradedNo reviewed efficacy summary in this indication
Pitolisant GR
—(overall)
Small moleculeHistamine H3 receptor (antagonist / inverse agonist)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Sodium Oxybate to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (4)
June 2027 (1)
Phase 2NarcolepsyRecruiting
Est. primary completion 2027-06 · NCT06809803 · CT.gov ↗
What to watch
September 2027 (1)
Phase 1Spasmodic Dysphonia, Laryngeal Dystonia, Voice TremorNot yet recruiting
Est. primary completion 2027-09-30 · NCT07041203 · CT.gov ↗
What to watch
October 2027 (1)
Phase 2Sleep Disorder (Disorder), Critical CareNot yet recruiting
Est. primary completion 2027-10 · NCT07596342 · CT.gov ↗
What to watch
December 2027 (1)
Early phase / not applicableThoracic Surgical ProceduresRecruiting
Est. primary completion 2027-12 · NCT07794982 · CT.gov ↗
What to watch

See the full readout calendar ↗